Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 500 milligram(s) - fluoroquinolones; levofloxacin - quinolone antibacterials, fluoroquinolones - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin - pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones, - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections

European Union - English - EMA (European Medicines Agency)

bayer animal health gmbh  - pradofloxacin - antibacterials for systemic use, fluoroquinolones - dogs; cats - dogstreatment of:wound infections caused by susceptible strains of the staphylococcus intermedius group (including s. pseudintermedius);superficial and deep pyoderma caused by susceptible strains of the staphylococcus intermedius group (including s. pseudintermedius);acute urinary-tract infections caused by susceptible strains of escherichia coli and the staphylococcus intermedius group (including s. pseudintermedius);as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example porphyromonas spp. and prevotella spp.catstreatment of acute infections of the upper respiratory tract caused by susceptible strains of pasteurella multocida, escherichia coli and the staphylococcus intermedius group (including s. pseudintermedius).

European Union - English - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - community-acquired infections - antibacterials for systemic use, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

sanofi israel ltd - levofloxacin as hemihydrate - film coated tablets - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - tavanic tablets 500 mg is indicated in adults for the treatment of the following infections:- acute pyelonephritis and complicated urinary tract infections - chronic bacterial prostatitisin the below-mentioned infections, tavanic should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.- acute bacterial sinusitis - acute exacerbations of chronic obstructive pulmonary disease including bronchitis - community-acquired pneumonia- complicated skin and soft tissue infections.tavanic may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - moxifloxacin hcl eqv moxifloxacin - tablet, film coated - 400 mg - moxifloxacin hcl eqv moxifloxacin 400 mg

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - moxifloxacin hcl eqv moxifloxacin - injection - 400 mg/250 ml - moxifloxacin hcl eqv moxifloxacin 400 mg/250 ml

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - moxifloxacin hydrochloride - film coated tablet - 400 milligram - fluoroquinolones - quinolone antibacterials, fluoroquinolones - it is indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin: - acute bacterial sinusitis (adequately diagnosed) - acute exacerbations of chronic bronchitis (adequately diagnosed) - community acquired pneumonia, except severe cases - mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess. it may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications: - community-acquired pneumonia - complicated skin and skin structure infections

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - levofloxacin hemihydrate - oral tablet - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - levofloxacin - solution for infusion - 5 milligram(s)/millilitre - fluoroquinolones; levofloxacin